Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:acquiredBy |
Arcinova
Co-Formulate |
| gptkbp:CEO |
Mark Egerton
|
| gptkbp:formerName |
Quotient Clinical
|
| gptkbp:foundedYear |
1990
|
| gptkbp:headquartersLocation |
gptkb:Nottingham,_United_Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
Quotient Sciences
|
| gptkbp:industry |
pharmaceuticals
drug development |
| gptkbp:numberOfEmployees |
over 900
|
| gptkbp:offersService |
formulation development
manufacturing services clinical trial services drug development services |
| gptkbp:operatesIn |
gptkb:Europe
gptkb:United_Kingdom gptkb:United_States |
| gptkbp:parentCompany |
gptkb:Permira
|
| gptkbp:specializesIn |
translational pharmaceutics
|
| gptkbp:website |
https://www.quotientsciences.com/
|
| gptkbp:bfsParent |
gptkb:Fine_Structure_Ventures
|
| gptkbp:bfsLayer |
7
|